The Danish health authority announced on Monday, May 3, that it was not going to use Johnson & Johnson’s anti-Covid vaccine because of “possible serious side effects”.
In a statement, the authority announces that it has concluded “that the advantages of the use of the COVVI-19 -9 vaccine by Johnson & Johnson do not prevail over the risk of causing a possible adverse effect, the VITT (a very rare type of thrombosis linked to the injection of the serum), in people who receive the vaccine”.
Denmark had also given up the Astrazeneca vaccine for the same risks of thrombosis.
The European Regulator and the World Health Organization (WHO), however, had given them both green light to the use of this viral vector unidose vaccine within the European Union.
The American vaccine Johnson & Johnson had been authorized by the Tunisian health authorities. The Minister of Health, Faouzi Mehdi announced, on April 8, 2021, that the Tunisian State granted his authorization to this vaccine.
He also announced that Tunisia should receive 1.5 million doses of this vaccine, as part of the African Union initiative.
The Janssen vaccine by Johnson & Johnson against COVVI-19 is a single dose and has been developed from adenovirus. It is deemed to be very effective in the severe forms of the disease (more than 76%) including on South African and Brazilian variants.
